Clinical Trials Conditions Microdosing 
CannaMD
SEPTEMBER 9, 2020
Published only recently, in May of 2020, this clinical trial is the first to show that microdoses of cannabis can be just as effective as much higher doses. What is microdosing? The concept of microdosing is pretty simple. The premise behind marijuana microdosing is equally straightforward. Translation?
Cannabis Law Report
JULY 25, 2022
million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). The state agency grant funding followed the successful completion of a phase 1 clinical trial in 80 healthy participants.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Joint Blog
NOVEMBER 15, 2021
While over the last few years, microdosing has become extremely popular, the act of microdosing has been recommended by experts for at least two decades. There are also many different substances that you can microdose, from psilocybin mushrooms to delta-8. In this article, we are going to cover microdose of legal substances.
The Cannigma
DECEMBER 12, 2022
And while most psychedelics are currently illegal in the United States and around the world, researchers are exploring their use in medicine to treat conditions such as depression, PTSD, addiction, anxiety, OCD, migraines, end of life acceptance of mortality, and eating disorders. What is microdosing? How do psychedelics work?
Veriheal
MARCH 20, 2023
Using psilocybin in small doses, or microdosing, has been shown to aid in the treatment of various mental health issues, including anxiety, depression, PTSD, and obsessive-compulsive disorder. Smith cited results from clinical trials showing that MDMA holds promise in the treatment of PTSD. Missouri Rep.
Cannabis Law Report
DECEMBER 2, 2021
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.
Cannabis Law Report
JUNE 19, 2022
For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art. Originally Published At Microdose. However, that does not mean that the path to patents is closed off.
Expert insights. Personalized for you.
111 
Let's personalize your content